| 货号 | 产品名 | 纯度 | ||
|---|---|---|---|---|
| A1440693 | 现货 |
Sacituzumab govitecan
Sacituzumab govitecan(Trodelvy)是一种抗体药物偶联物(ADC),由靶向Trop-2的单克隆抗体与拓扑异构酶I抑制剂SN-38连接而成。Sacituzumab govitecan 具有抗癌活性。 |
≥97% | |
| A2632379 |
Pinatuzumab Vedotin
|
99% | ||
| A1942445 |
Zilovertamab vedotin
|
99% | ||
| A1739503 |
Vorsetuzumab Mafodotin
|
99% | ||
| A1961328 |
Ladiratuzumab Vedotin
|
98% | ||
| A2740439 |
Ensituximab-MMAE
|
95% | ||
| A2740444 |
Sacituzumab-MMAE
|
95% | ||
| A2740433 |
Patritumab-MMAE
|
95% | ||
| A2251164 |
Telisotuzumab vedotin
|
99% | ||
| A2632375 |
Lorvotuzumab Mertansine
|
98% | ||
| A2632380 |
Farletuzumab-MMAE
|
95% | ||
| A2740438 |
Talacotuzumab-MMAE
|
95% | ||
| A2632374 |
Enapotamab Vedotin
|
99% | ||
| A1949785 |
Lifastuzumab Vedotin
|
99% | ||
| A2632383 |
Clivatuzumab-MMAE
|
95% | ||
| A2740426 |
Murlentamab-MMAE
|
95% | ||
| A1895176 |
Labetuzumab govitecan
|
99% | ||
| A1997047 |
Glembatumumab vedotin
|
99% | ||
| A1949773 |
Iladatuzumab Vedotin
|
99% | ||
| A2740437 |
Lonigutamab-MMAE
|
95% |
沪公网安备 31011702889066号
沪ICP备2024050318号-1